IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
Joanne Jones(University of Cambridge), Alasdair Coles(University of Cambridge), Jacqueline Shawcross(University of Cambridge), Stephen Sawcer(University of Cambridge), Alastair Compston(University of Cambridge), Sara Thompson(University of Cambridge), Amie Walton(University of Cambridge), Maria Ban(University of Cambridge), Amanda Cox(Sorbonne Université), Chia‐Ling Phuah(Barnes-Jewish Hospital)
Cited by 299
Related Papers
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
|Nature Genetics|2013|1.5k
Complex genetic signatures in immune cells underlie autoimmunity and inform therapy
|Nature Genetics|2020|1.3k
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
|Brain|2009|962
Multiple Sclerosis Severity Score
|Neurology|2005|959